Are 'natty stacks' just overpriced peptides repackaged?

What did @clay.cognitiv actually say?

The creator argues that Alpha Brain's ingredient list, theanine, phosphatidylserine (PS), alpha-GPC, huperzine A, and vitamin B6, can be replicated and improved for roughly the same $80 price point by swapping in selank, P5P (pyridoxal-5-phosphate), and what sounds like nefiracetam. The central pitch is that the branded product is overpriced and that a few targeted substitutions would produce a meaningfully superior stack. That is a reasonable consumer argument, and parts of it are well-grounded. But some of the specific mechanistic claims are either oversimplified or outright wrong, and at least one ingredient substitution carries real safety considerations that got zero airtime.

The video is clearly aimed at people who already know what these compounds are, given the hashtag "natty" and the peptide category framing. That audience deserves more precision than they got here.

Does the science back this up?

Partially. The core acetylcholine-support logic, pairing a choline precursor like alpha-GPC with an acetylcholinesterase inhibitor like huperzine A, is a legitimate and studied nootropic strategy. The PS research is real. The P5P swap is genuinely defensible. But the selank claim and the nefiracetam framing need scrutiny.

On PS: Crook et al. (1991, Neurology) found PS supplementation improved memory tasks in older adults with age-associated memory impairment, and the rat data on acetylcholine the creator references aligns with Nunzi et al. (1987, Psychopharmacology Bulletin). The effect sizes in humans are modest, but the mechanism is plausible.

On selank as a GABA enhancer: selank is a synthetic heptapeptide developed by the Russian Academy of Sciences. It does appear to modulate GABAergic tone, but calling it a simple GABA booster the way theanine is described understates how differently these compounds work. Selank's anxiolytic effects likely involve BDNF upregulation and enkephalin metabolism, not just GABA (Semenova et al., 2010, CNS Drug Reviews). The creator's framing collapses a nuanced mechanism into a clean marketing-style swap.

On alpha-GPC staying in: yes, it is a reasonably bioavailable choline donor. A 2003 multicenter trial (De Jesus Moreno Moreno, Archives of Medical Research) supported its use in Alzheimer's-related cognitive decline. It belongs.

What did they get wrong (or right)?

They got the P5P call right. Standard pyridoxine requires conversion to P5P in the liver, and individuals with MTHFR variants or compromised hepatic function may not convert efficiently. Substituting activated B6 is a straightforward upgrade with essentially no downside. Credit where it is due.

The huperzine A "we have something better" pivot is where things get murky. The creator seems to be gesturing toward nefiracetam ("nebazil" appears to be a mispronunciation or transcription artifact), describing it as an acetylcholinesterase inhibitor. Nefiracetam does enhance cholinergic transmission, but it is not primarily an acetylcholinesterase inhibitor. Its mechanism involves potentiating nicotinic acetylcholine receptors and modulating protein kinase C (Nishizaki et al., 2000, Brain Research). Calling it a direct replacement for huperzine A based on shared acetylcholine-adjacent effects is sloppy. Huperzine A has a well-characterized inhibitory mechanism. Nefiracetam does not work the same way.

Also worth noting: huperzine A accumulates with daily use and can cause cholinergic overstimulation. The video does not mention cycling. That omission matters for an audience that might just start adding compounds to a stack.

What should you actually know?

Building your own nootropic stack is not inherently dangerous, but it requires more rigor than this video provides. A few things the video skipped entirely:

• Selank is not a standard supplement. It is a research peptide with limited human trial data outside Russia. Sourcing, purity, and dosing are real variables that a DIY stack video should not gloss over.
• Huperzine A has a narrow therapeutic window. Adding nefiracetam or any other cholinergic-enhancing compound without understanding cumulative load raises risk.
• The price comparison math is presented as obvious, but it depends entirely on sourcing channels the creator does not name. Peptide and racetam quality varies enormously by vendor.
• P5P at high doses can cause peripheral neuropathy. The "more effective all around" characterization is true at physiological doses but not a blanket endorsement for going higher.

If you are considering a custom nootropic stack, particularly one that includes research peptides like selank, a telehealth consultation is worth the time. These are not candy vitamins.